source
- Dimerix acquires Mission's phase-2 ready AKI drug in $292 million dealDimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…
- India’s life-sciences sector faces scaling hurdles despite rapid innovation growth, report saysIndia’s life‑sciences sector has shown rapid growth, according to a new report by Boston Consulting Group and HealthKois. Patent filings have risen more than four‑fold since 2016, the pipeline of i…